Objective: To investigate the clinical effect of Daclizumab on preventing acute rejection in renal transplant recipients.Methods: 71 patients were randomly divided into two groups: Daclizumab group (n =26) and control group (n = 45). Baselineregimen of mycophenolate mofetil(MMF), cyclosporin(CsA), methylprednisolone(MPD) and prednisone(Pred) were adminis-tered to all patients. The treatment of Daclizumab was based on baseline regimen. The Daclizumab group received Daclizumabtwice before and after renal transplant. The occurrence of post-transplantation acute rejection, renal function and T lymphocytesubtypes were sequentially monitored; meanwhile adverse events, infection episode, and patient and graft survival were observed.All of patients received a follow-up of 12 months at least. Results: The occurrence of acute rejection in Daclizumab group in 1,3, 6 and 12 months after renal transplantation was 7.7%, 19.2%, 23.1% and 30.8%, respectively, while it was 15.6%, 28.9%,35.6% and 46.7% in the control group. There was significant difference between the two group(P < 0.05). There was no differencein infection episodes and adverse events between the Daclizumab group and control group. One year patient survival was 92.3% inDaclizumab group, 91.1 % in control group (P > 0.05), compared with graft survival of 96.2 % and 93.3 % for Daclizumab andcontrol group, respectively (P > 0. 05). The renal function in Daclizumab group in 1, 6 and 12 months after renal transplantationwas better than that in control group (P < 0.05). The CD3+ and CD4+ subtypes decreased in both two groups after operation butno significant difference(P > 0.05). Conclusion: Daclizumab combined with MMF, CsA, MPD and Pred therapeutic regimen waseffective to reduce the occurrence of acute rejection in renal transplant recipients and have no influence on T lymphocyte subtypes. Objective: To investigate the clinical effect of Daclizumab on preventing acute rejection in renal transplant recipients. Methods: 71 patients were randomly divided into two groups: Daclizumab group (n = 26) and control group (n = 45). Baseline regimen of mycophenolate mofetil The treatment of Daclizumab was based on baseline regimen. The Daclizumab group received Daclizumabtwice before and after renal transplant. The occurrence of post (MMF) -transplantation acute rejection, renal function and T lymphocytesubtypes were previously monitored monitored; meanwhile adverse events, infection episode, and patient and graft survival were observed. All of patients received a follow-up of 12 months at least. Results: The occurrence of acute rejection in Daclizumab group in 1,3, 6 and 12 months after renal transplantation was 7.7%, 19.2%, 23.1% and 30.8%, respectively, while it was 15.6%, 28.9%, 35.6% and 46.7% There was no difference in infection episodes and adverse events between the Daclizumab group and control group. One year patient survival was 92.3% in DAClizumab group, 91.1% in control group (P> 0.05), compared with graft survival of 96.2% and 93.3% for Daclizumab and control group, respectively (P> 0.05). The renal function in Daclizumab group in 1, 6 and 12 months after renal transplantation was better than that in control group (P <0.05). The CD3 + and CD4 + subtypes decreased in both two groups after operation but no significant difference (P> 0.05). Conclusion: Daclizumab combined with MMF, CsA, MPD and Pred therapeutic regimen waseffective to reduce the occurrence of acute rejection in renal transplant recipients and have no influence on T lymphocyte subtypes.